Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

doi:10.1016/j.intimp.2021.108200

Review

. 2021 Dec;101(Pt A):108200.

doi: 10.1016/j.intimp.2021.108200. Epub 2021 Sep 28.

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Affiliations

¹ Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
² Unit of Infectious Diseases, Cardinal Massaia Hospital, Asti, Italy. Electronic address: tommaso.lupia89@gmail.com.
³ S.C. Farmacia Ospedaliera -A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
⁴ Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy; Tufts University School of Medicine, Boston, MA, USA.

PMID: 34607231
PMCID: PMC8479899
DOI: 10.1016/j.intimp.2021.108200

Review

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Simone Mornese Pinna et al. Int Immunopharmacol. 2021 Dec.

. 2021 Dec;101(Pt A):108200.

doi: 10.1016/j.intimp.2021.108200. Epub 2021 Sep 28.

Affiliations

¹ Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
² Unit of Infectious Diseases, Cardinal Massaia Hospital, Asti, Italy. Electronic address: tommaso.lupia89@gmail.com.
³ S.C. Farmacia Ospedaliera -A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
⁴ Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy; Tufts University School of Medicine, Boston, MA, USA.

PMID: 34607231
PMCID: PMC8479899
DOI: 10.1016/j.intimp.2021.108200

Abstract

The world is facing up the most considerable vaccination effort in history to end the Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) direct against the Receptor binding domain of the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) received an Emergency Use Authorization for outpatient management of mild to moderate manifestation from COVID-19. MAbs could prevent the transmission SARS-CoV-2 infection and protect individuals from progression to severe disease. Under the pressure of different treatment strategies, SARS-CoV-2 has been demonstrated to select for different sets of mutations named "variants" that could impair the effectiveness of mAbs by modifying target epitopes. We provide an overview of both completed and unpublished, or ongoing clinical trials of mAbs used and review state of art in order to describe clinical options, possible indications, and the place in therapy for these agents in the treatment of COVID-19 with a particular focus on anti-spike agents. Then, we reassume the current evidence on mutations of the SARS-CoV-2 that might confer resistance to neutralization by multiple mAbs.

Keywords: COVID-19; Monoclonal antibodies; Pneumonia; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

**Fig. 1**
Advantages and Weaknesses of Casirivimab and Imdevimab.

**Fig. 2**
Advantages and Weaknesses of Bamlanivimab and Etesevimab.

See this image and copyright information in PMC

Cited by

Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series.
Longo BM, Venuti F, Gaviraghi A, Lupia T, Ranzani FA, Pepe A, Ponzetta L, Vita D, Allice T, Gregorc V, Frascione PMM, De Rosa FG, Calcagno A, Bonora S. Longo BM, et al. Antibiotics (Basel). 2023 Sep 19;12(9):1460. doi: 10.3390/antibiotics12091460. Antibiotics (Basel). 2023. PMID: 37760757 Free PMC article.
A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.
Knopp BW, Weiss HZ, Fahmy S, Goldstein E, Parmar J. Knopp BW, et al. Cureus. 2023 Aug 7;15(8):e43094. doi: 10.7759/cureus.43094. eCollection 2023 Aug. Cureus. 2023. PMID: 37680398 Free PMC article.
Application of machine learning approach in emergency department to support clinical decision making for SARS-CoV-2 infected patients.
Casano N, Santini SJ, Vittorini P, Sinatti G, Carducci P, Mastroianni CM, Ciardi MR, Pasculli P, Petrucci E, Marinangeli F, Balsano C. Casano N, et al. J Integr Bioinform. 2023 Mar 7;20(2):20220047. doi: 10.1515/jib-2022-0047. eCollection 2023 Jun 1. J Integr Bioinform. 2023. PMID: 36877860 Free PMC article.
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19.
de Almeida Oliveira A, Praia Borges Freire D, Rodrigues de Andrade A, de Miranda Marques A, da Silva Madeira L, Moreno Senna JP, Freitas Brasileiro da Silveira IA, de Castro Fialho B. de Almeida Oliveira A, et al. J Pharm Innov. 2023 Feb 20:1-19. doi: 10.1007/s12247-023-09713-w. Online ahead of print. J Pharm Innov. 2023. PMID: 36843665 Free PMC article.
Development of a validated molecular analytical method to determine the viral safety of F(AB´)₂ products: A novel application for a well-known technique.
Sánchez-Pacheco UA, Bahena-Mondragón BM, Hernández-Piedras FR, Soria-Osorio R, Meneses-Acosta A. Sánchez-Pacheco UA, et al. J Virol Methods. 2023 May;315:114694. doi: 10.1016/j.jviromet.2023.114694. Epub 2023 Feb 22. J Virol Methods. 2023. PMID: 36822561 Free PMC article.

See all "Cited by" articles

References

1. Azer S.A. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020;37 doi: 10.1016/j.nmni.2020.100738. - DOI - PMC - PubMed
1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32150360. - PubMed
1. Mehta R.M., Bansal S., Bysani S., Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. Int J Infect Dis. 2021;106:71–77. doi: 10.1016/j.ijid.2021.02.092. - DOI - PMC - PubMed
1. Mongardon N, Piagnerelli M, Grimaldi D, Perrot B, Lascarrou JB; COVADIS study group investigators. Impact of late administration of corticosteroids in COVID-19 ARDS. Intensive Care Med. 2021 Jan;47(1):110-112. doi: 10.1007/s00134-020-06311-z. Epub 2020 Nov 6. PMID: 33156381; PMCID: PMC7645397. - PMC - PubMed
1. Liu J., Zhang S., Dong X., Li Z., Xu Q., Feng H., Cai J., Huang S., Guo J., Zhang L., Chen Y., Zhu W., Du H., Liu Y., Wang T., Chen L., Wen Z., Annane D., Qu J., Chen D. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020 Dec 1;130(12):6417–6428. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Azer S.A. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020;37 doi: 10.1016/j.nmni.2020.100738. - DOI - PMC - PubMed

[2] Azer S.A. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020;37 doi: 10.1016/j.nmni.2020.100738. - DOI - PMC - PubMed

[3] Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32150360. - PubMed

[4] Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32150360. - PubMed

[5] Mehta R.M., Bansal S., Bysani S., Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. Int J Infect Dis. 2021;106:71–77. doi: 10.1016/j.ijid.2021.02.092. - DOI - PMC - PubMed

[6] Mehta R.M., Bansal S., Bysani S., Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. Int J Infect Dis. 2021;106:71–77. doi: 10.1016/j.ijid.2021.02.092. - DOI - PMC - PubMed

[7] Mongardon N, Piagnerelli M, Grimaldi D, Perrot B, Lascarrou JB; COVADIS study group investigators. Impact of late administration of corticosteroids in COVID-19 ARDS. Intensive Care Med. 2021 Jan;47(1):110-112. doi: 10.1007/s00134-020-06311-z. Epub 2020 Nov 6. PMID: 33156381; PMCID: PMC7645397. - PMC - PubMed

[8] Mongardon N, Piagnerelli M, Grimaldi D, Perrot B, Lascarrou JB; COVADIS study group investigators. Impact of late administration of corticosteroids in COVID-19 ARDS. Intensive Care Med. 2021 Jan;47(1):110-112. doi: 10.1007/s00134-020-06311-z. Epub 2020 Nov 6. PMID: 33156381; PMCID: PMC7645397. - PMC - PubMed

[9] Liu J., Zhang S., Dong X., Li Z., Xu Q., Feng H., Cai J., Huang S., Guo J., Zhang L., Chen Y., Zhu W., Du H., Liu Y., Wang T., Chen L., Wen Z., Annane D., Qu J., Chen D. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020 Dec 1;130(12):6417–6428. - PMC - PubMed

[10] Liu J., Zhang S., Dong X., Li Z., Xu Q., Feng H., Cai J., Huang S., Guo J., Zhang L., Chen Y., Zhu W., Du H., Liu Y., Wang T., Chen L., Wen Z., Annane D., Qu J., Chen D. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020 Dec 1;130(12):6417–6428. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Affiliations

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous